Suppr超能文献

不同变应原剂量递增方案对蜂毒免疫治疗患者血清 CTLA-4 和 IL-10 的影响。

Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10.

机构信息

Allergy and Respiratory Diseases, Department of Internal Medicine, University of Genoa, Genoa, Italy.

出版信息

PLoS One. 2012;7(6):e37980. doi: 10.1371/journal.pone.0037980. Epub 2012 Jun 19.

Abstract

BACKGROUND

Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down regulated by immunotherapy.

OBJECTIVE

to assess the effects on CTLA-4 of venom immunotherapy, given with different induction protocols: conventional (6 weeks), rush (3 days) or ultra rush (1 day).

METHODS

Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase. CTLA-4 and IL-10 were assayed in the same samples. A subset of patients were assayed also after 12 months of VIT maintenance.

RESULTS

Ninety-four patients were studied. Of them, 50 underwent the conventional induction, 20 the rush and 24 the ultra-rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction, irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, IL-10 significantly increased at the end of the induction. At 12 months, sCTLA-4 remained low, whereas IL-10 returned to the baseline values.

CONCLUSIONS

Serum CTLA4 is an early marker of the immunological effects of venom immunotherapy, and its changes persist after one year of maintenance treatment.

摘要

背景

细胞毒性 T 淋巴细胞相关抗原 4(CTLA-4)参与 T 淋巴细胞的激活途径。已经表明,变应原性蜂类过敏患者的循环 CTLA-4 水平升高,并且可以通过免疫疗法下调。

目的

评估不同诱导方案(常规(6 周)、快速(3 天)或超快速(1 天))下毒液免疫疗法对 CTLA-4 的影响。

方法

在基线和诱导阶段结束时收集变应原性蜂类过敏患者的血清。在相同的样本中检测 CTLA-4 和 IL-10。一小部分患者在 VIT 维持 12 个月后也进行了检测。

结果

共研究了 94 名患者。其中,50 名患者接受常规诱导,20 名患者接受快速诱导,24 名患者接受超快速诱导。所有患者在基线时均可检测到可溶性 CTLA-4,并且无论诱导持续时间如何,诱导结束时均显著降低。值得注意的是,在 24 小时即可观察到 sCTLA-4 的显著下降。同时,IL-10 在诱导结束时显著增加。在 12 个月时,sCTLA-4 仍然较低,而 IL-10 恢复到基线值。

结论

血清 CTLA4 是毒液免疫疗法免疫效应的早期标志物,并且在维持治疗 1 年后其变化仍然存在。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d7/3378587/5870077aaeef/pone.0037980.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验